指南与共识造血干细胞移植与细胞治疗

英国异基因造血干细胞移植后嵌合体检测与监测建议:BSBMTCT、NHS England GLH、UKCGG与UK NEQAS LI最佳实践共识指南

UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Qu
指南 / 共识 · Br J Haematol · 2025-09-09

该共识由英国多家机构联合制定,针对异基因造血干细胞移植后嵌合体检测与监测提出最佳实践建议。内容涵盖检测方法、细胞亚群选择、检测频率、周转时间、与可测量残留病监测的衔接及移植后检测持续时间,并指出未来审计与研究的关键领域。

要点

  • 嵌合体评估影响免疫抑制剂剂量与供者淋巴细胞输注等关键临床决策。
  • 检测方法、细胞亚群、频率、周转时间及移植后监测时长需按疾病、患者、供者与移植强度调整。
  • 共识旨在促进英国临床与实验室实践的统一,并提出未来审计与研究重点。

核心结论

  • 该共识提出异基因造血干细胞移植后嵌合体检测与监测的最佳实践建议,并识别未来审计与研究的关键领域。

研究设计与样本

  • 英国癌症遗传学组(UKCGG)、NHS England基因组实验室中心(GLH)血液肿瘤恶性工作组、英国白细胞免疫表型国家外部质量评估服务(UK NEQAS LI)与英国血液与骨髓移植及细胞治疗学会(BSBMTCT)联合召开全国研讨会,回顾当前文献并制定最佳实践共识建议。

主要发现

  • 嵌合体评估用于免疫抑制剂剂量调整和供者淋巴细胞输注等临床决策,可影响疾病控制、移植物抗宿主病、免疫及患者生存。
  • 检测需考虑方法学、细胞亚群选择、检测频率、周转时间紧迫性、与可测量残留病监测的衔接及移植后检测持续时间。
  • 上述方面常规根据疾病指征、患者特征、供者来源和移植技术强度进行调整。

临床怎么用

  • 原文未据此给出具体推荐条款。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In allogeneic haematopoietic stem cell transplantation (HSCT), important clinical decisions depend upon assessment of chimerism, including immunosuppressant dosing and donor lymphocyte infusions (DLI), which in turn can have major impacts on disease control, graft-versus-host disease (GVHD), immunity and ultimately patient survival. There is a complex range of clinical and laboratory procedural considerations including methodology of testing, types of cell subset selection, frequency of testing, urgency of turnaround times (TATs), interplay with measurable residual disease (MRD) monitoring and duration of testing post-transplant. These aspects are routinely adapted according to disease indication, patient characteristics, donor source and intensity of transplant technique. To encourage the harmonisation of clinical and laboratory practice in the United Kingdom, we held a national workshop meeting to bring together key stakeholders to review the current literature with a view to producing a state-of-the-art position paper. Here, we present best practice consensus recommendations and identify key areas for future audit and research from the UK Cancer Genetics Group (UKCGG), NHS England Genomic Laboratory Hub (GLH) Haematological Oncology Malignancies Working Group, UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI) and the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Clark A, Clouston H, Rao K, et al. UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI). Br J Haematol. 2025. PMID: 40926330. doi:10.1111/bjh.70061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。